Precision medicine is becoming increasingly integrated into healthcare, which is causing a revolutionary change in the industry. Comprehensive genomic profiling (CGP) and sophisticated diagnostics are two cutting-edge discoveries that have the potential to completely transform patient care by providing highly individualized treatment plans. Though these innovative technologies have great potential, getting market access is extremely difficult for them.[1]

Advanced diagnostics refers to a wide range of technologies designed to identify conditions early on, forecast the course of diseases, and accurately track the effectiveness of treatment. CGP typically includes all major classes of genomic variants (single nucleotide variants, indels, copy number variants, fusions, and splice variants) and is capable of detecting biomarkers at nucleotide-level precision. Furthermore, CGP maximizes the potential to identify clinically actionable mutations by detecting genomic signals such as TMB and MSI (tumor mutational burden and microsatellite instability, respectively). Across a variety of tumor types, numerous studies have shown that CGP can detect genetic abnormalities that may be clinically significant.[1,2]

Since the number of targeted medicines is expanding quickly, molecular profiling could be very beneficial to many patients.  These include the development of innovative medicines for less common gene changes, such as NTRK fusions, which account for less than 1% of all cancer cases.  When combined, these technologies can enable precision medicine, which could lead to a major improvement in patient outcomes, especially in oncology. To assist reduce tissue use and potential waste, for example, CGP can identify specific genetic abnormalities driving tumor growth in cancer treatment, enabling clinicians to choose tailored medicines that are more likely to be beneficial.[3,4]

The market access challenges that advanced diagnostics and CGP encounter are manifold and can be largely classified into three categories: practical, economic, and regulatory. Gaining regulatory approval is a significant challenge that calls for a thorough assessment to prove clinical validity, usefulness, and safety. Though regulatory organizations are increasingly realising the need for adaptive frameworks to keep pace with technical breakthroughs, the quickly evolving nature of genomic technologies often outpaces regulatory rules, producing a lag between invention and clearance.[5]

One major financial barrier is the high cost of CGP and sophisticated diagnostics. The cost of testing is increased by these technologies since they sometimes require specialized chemicals, pricey equipment, and knowledgeable staff.  The cost-benefit ratio must be taken into account by healthcare providers and payers, who must weigh the significant long-term advantages of precision medicine against its exorbitant upfront costs. Reimbursement policies are critical, necessitating persuading payers of the benefits of these technologies, such as insurance companies and government health programs. In order to obtain favorable payment terms, it is imperative to demonstrate cost-effectiveness through comprehensive health economic studies. Failure to do so may result in healthcare providers being unwilling to implement these technologies, hence restricting patient access. [6]

The incorporation of CGP and advanced diagnostics into clinical practice requires substantial modifications to current procedures.  Healthcare facilities must make investments in the equipment required, such as genomic sequencing labs and bioinformatics platforms, and provide their clinicians with the appropriate training to analyze complicated genomic data and apply these insights to treatment decisions. Furthermore, patient education is essential because patients must comprehend the possible advantages and restrictions of genetic testing in addition to the consequences of the findings. To guarantee that decisions are well-informed, physicians and patients must communicate effectively. [6]

Advanced diagnostics and CGP can enter the market more easily through a number of techniques. Firstly, it is imperative to involve important parties early on in the commercialization process, including administrators, payers, lawmakers, regulators, and healthcare providers. Firstly, it is imperative to involve important parties early on in the commercialization process, including administrators, payers, lawmakers, regulators, and healthcare providers. Firstly, it is imperative to involve important parties early on in the commercialization process, including administrators, payers, lawmakers, regulators, and healthcare providers. Thirdly, successful commercialization requires the involvement of the entire organization; all key departments need to be aware of what is needed to launch and scale an advanced diagnostic. Innovators should start small, with a dedicated staff leading market growth with early adopters, then grow when coding, coverage, and payment structures are established. Preparing for the long term is another key strategy, as the commercialization process for advanced diagnostics is lengthy. It is recommended that innovators invest substantial resources across ten years or more, while also maintaining flexibility to adjust to the needs of the diagnostic test. Finally, given the sizeable total addressable markets and promising biomarkers for numerous tests in development, investors should assess possible investments based on the clinical value of the diagnostic test and its route to reimbursement and access.[4-6]

Precision medicine has the potential to transform patient care through the use of advanced diagnostics and CGP.  Stakeholders can help integrate these innovations into mainstream healthcare by adopting cooperative regulatory frameworks, proving economic benefits, developing clinical capability, and improving patient participation. Although there are several obstacles in this process of general adoption, the potential benefits for better patient outcomes make the effort worthwhile.

Become A Certified HEOR Professional – Enrol yourself here!

References

1. Wheler JJ, Janku F, Naing A, et al. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res. 2016 Jul 1;76(13):3690-701.
2. Hirshfield KM, Tolkunov D, Zhong H. Clinical actionability of comprehensive genomic profiling for management of rare or refractory cancers. Oncologist. 2016 Nov;21(11):1315-1325.
3. Fabrizio, et al. Clinical and analytic validation of FoundationOne CDx for NTRK fusion-positive solid tumors in patients treated with entrectinib. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019. AACR; Mol Cancer Ther. 2019; Abstract A028.
4. Foundation Medicine. Why comprehensive genomic profiling? Available from: https://www.foundationmedicine.com/resource/why-comprehensive-genomic-profiling.
5. Svoboda M, Lohajova Behulova R, Slamka T, Sebest L, Repiska V. Comprehensive genomic profiling in predictive testing of cancer. Physiol Res. 2023;72(S3)–S275.
6. Snow S, Brezden-Masley C, Carter MD, Dhani N, Macaulay C, Ramjeesingh R, Raphael MJ, Slovinec D’Angelo M, Servidio-Italiano F. Barriers and unequal access to timely molecular testing results: addressing the inequities in cancer care delays across Canada. Curr Oncol. 2024;31(3):1359–75.